Table 1 Comparison of HBsAg-positive patients with HBsAg-negative patients
From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma
| Â | HBsAg-positive patients (No = 81)(30.9%) | HBsAg-negative patients (No = 181)(69.1%) | p-value |
|---|---|---|---|
Age (years) | Â | Â | 0.026 |
Range | 17–75 | 17–86 |  |
Median | 46 | 51 | Â |
Sex | Â | Â | 0.006 |
Male | 41(50.6) | 124(68.5) | Â |
Female | 40(49.4) | 57(31.5) | Â |
Stage | Â | Â | 0.016 |
I/II | 34(42) | 105 (58) | Â |
III/IV | 47(58) | 76(42) | Â |
Liver involvement | Â | Â | 0.027 |
Yes | 8(9.9) | 5(2.8) | Â |
No | 73(90.1) | 176(97.2) | Â |
Spleen involvement | Â | Â | 0.024 |
Yes | 12(14.8) | 11(6.1) | Â |
No | 69(85.2) | 170(93.9) | Â |
LDH increase | Â | Â | 0.89 |
> normal | 40(49.4) | 91(50.3) | Â |
normal | 41(50.6) | 90(49.7) | Â |
Extra node involvement | Â | Â | 0.034 |
≤ 1 | 69(85.2) | 169(93.4) |  |
> 1 | 12(14.8) | 12(6.6) | Â |
PS | Â | Â | 0.26 |
≤ 1 | 76(93.8) | 162(89.5) |  |
> 1 | 5(6.2) | 19(10.5) | Â |
IPI | Â | Â | 0.99 |
0,1 | 46(57) | 103(57) | Â |
2,3,4 | 35(43) | 78(43) | Â |
Chemotherapy | Â | Â | 0.69 |
Range | 1–20 | 1–16 |  |
Median | 6 | 6 | Â |
Radiation | Â | Â | 0.61 |
Yes | 26(32.1) | 64(35.4) | Â |
No | 55(67.9) | 117(64.6) | Â |
Response | Â | Â | 0.24 |
CR | 43(53) | 103(61.7) | Â |
PR | 31(38) | 48(28.7) | Â |
SD | 5(6) | 8(4.8) | Â |
PD | 3(3) | 8(4.8) | Â |
NA | Â | 14 | Â |
Hepatic dysfunction before chemotherapy | 17(21) | 10(5.5) | < 0.001 |
Hepatic dysfunction during chemotherapy | 40(49.4) | 30(16.6) | < 0.001 |